Background: Spleen and liver assessment for occult involvement of Hodgkin's lymphoma (HL) challenges current staging procedures.
sensitivity ranging from 33% to 94% for CT and from 50% to 100% for PET [13, 14] .
Spleen or liver evaluation is challenging since splenomegaly or hepatomegaly may occur even if these organs are not involved by the disease (hyperplastic or congestive enlargement) and, conversely, the involvement does not necessarily imply spleen or liver enlargement. Pathological staging procedures have indicated that infiltration in these organs frequently presents with small nodules [6] [7] [8] [9] 13] . We recently reported a large series of patients with HL who were staged with FDG-PET and contrast-enhanced CT separately carried out and then viewed side by side (side-by-side PET + CT). The study showed that this imaging modality failed to detect 57% of spleen involvements, mainly £1-cm nodules, thus resulting in disease understaging in 13% of patients compared with contrast-enhanced harmonic compound ultrasonography [15] . Other groups have reported that the combination of FDG-PET and contrast-enhanced CT, using, on the same occasion, CT for attenuation correction and FDG-avid lesion anatomic location as well as for diagnostic information (fused PET/CT), optimizes detection of occult abdominal involvement [16] , particularly nodular infiltration in spleen and/or liver [17] [18] [19] [20] . Based on these data, fused FDG-PET/CT is used in our center as a frontline single imaging diagnostic tool to tailor the treatment of HL to the individual patient. However, it is not known whether patient outcome differs in relation to the staging procedure used [10] [11] [12] . To address this issue, we conducted a prospective study in patients with HL who referred to our institution for therapy based on staging that included fused FDG-PET/CT. We then compared event-free survival (EFS) of these patients with that of a historical cohort of HL patients, previously referring to our institution for therapy based on staging that included side-by-side PET + CT.
patients and methods patients
One hundred thirty-three consecutive patients with histologically proved HL [21] who referred to our institution between January 2007 and August 2009 were screened for enrollment. Eligible criteria were newly diagnosed and untreated HL, age <75 years, World Health Organization performance score 0-3, and Ann Arbor/Cotswolds stages I-IV [22, 23] . Bulky disease was defined as single lymph node or conglomerate nodal mass with a long axis ‡5 cm. Pretreatment staging included a detailed history and physical examination, complete blood studies, bone marrow biopsy, and fused FDG-PET/contrast-enhanced CT. This group is designated 'fused PET/CT' because this imaging modality was included in the frame of diagnostic work-up. Only patients who completed all the treatment scheduled on the basis of complete staging and for whom adequate post-treatment data (defined as clinical and radiological follow-up every 3-6 months) were available were included in the final analysis. Patients not undergoing the staging procedures, patients with therapy reduction and/or delay owing to co-morbidities or toxicity during treatment, and patients lost to follow-up were excluded.
A historical cohort of 132 consecutive patients with histologically proved HL [21] and who referred to our Institution between January 2004 and December 2006, were considered for comparison purposes. Inclusion and exclusion criteria for the final analysis were the same as for the fused PET/ CT group. The historical cohort patients underwent therapy based on the same staging as the fused PET/CT group, except that FDG PET and contrast-enhanced CT were carried out separately.
The study took place at the Hematology Division of the University of Naples 'Federico II' University School of Medicine and the 'Fondazione SDN' of Naples (Italy), after institutional review board approval. Informed consent to staging and to receive treatment was obtained from all patients studied.
imaging procedures
All patients analyzed in the fused PET/CT group underwent, on a single occasion, whole-body FDG-PET/contrast-enhanced CT with a combined in-line system (Discovery LS; GE Medical Systems, Milwaukee, WI) that integrates a four-detector-row spiral CT (Lightspeed Ultra; GE Medical Systems) with a PET scanner (Discovery LS8; GE Medical Systems). FDG was produced in on-site cyclotron and chemistry facilities. A dose of 5.3 6 1 MBq/kg of FDG was i.v. injected 60 6 10 min before imaging. PET scans were carried out from the midbrain to upper thigh after an 8-h fast, with 2D emission scans of 4 min per bed position. Images (128 · 128 matrix) were obtained with an iterative ordered-subset expectation maximization (OSEM). The OSEM algorithm was applied to ratio sinograms using attenuation-weighted iterative reconstruction (two iterations, 28 subsets) and subsequent smoothing with a Hanning filter. Comparable axial resolutions (full width at half maximum 5.45 mm) were obtained according to the National Electrical Manufacturers Association NU 2001 test procedure. Unenhanced low-dose CT for segmented attenuation correction was carried out in each patient; immediately after, PET scans were acquired covering the same field of view as the CT. Then, contrast-enhanced CT was carried out using current at full dose (maximum, 300 mA) and 140 ml of nonionic contrast medium (Ultravist 370 mg I/ml; Bayer-Schering Pharma, Berlin, Germany) i.v. injected at a rate of 2 ml/s. Scans during hepatic arterial and portal venous phases were automatically started at 30 and 60 s, respectively, after contrast-agent injection [10] [11] [12] . FDG-PET and contrastenhanced CT datasets were viewed in fused mode using a special fusion workstation.
All patients analyzed in the historical cohort underwent on different days (within a median of 2 weeks, range 1-4 weeks) whole-body contrastenhanced CT (Mx8000; Marconi Medical Systems, Cleveland, OH) and FDG-PET (Advance NXi; GE Medical Systems). Diagnostic CT scans were carried out using the same parameters as those used for full-dose contrastenhanced CT in the fused PET/CT group. Similarly, FDG-PET was carried out using the same parameters as those used for FDG-PET in the fused PET/CT group. All PET images were attenuation corrected with Ge 68 source scans or unenhanced low-dose CT. FDG-PET and contrastenhanced CT images were viewed side by side.
All imaging tests were executed and read by expert radiologists and nuclear medicine physicians (AS and EN who have more than 5 years expertise with CT and PET) in consensus. In both the fused PET/CT group and the historical cohort, clinically suspected lesions were considered positive for lymphoma in cases of concordance for malignancy between the two imaging techniques [10-13, 18, 23] . When malignancy was found with only one technique (e.g. nodular hypodensity in spleen and/or liver at contrast-enhanced CT, without FDG focal uptake at PET scans, or vice versa), the lesion was interpreted as negative for lymphoma, i.e. this was not taken into account for final staging [23] .
treatment strategy
Patients of the fused PET/CT group and historical cohort underwent a combined treatment strategy consisting of VEBEP (vinblastine, etoposide, bleomycin, epirubicin, and prednisone) chemotherapy (routinely used for HL in our institution) and radiotherapy (if needed) [24] . The VEBEP regimen consisted of a 4-week course of the schedule shown in Figure 1 . Filgrastim was administered from day 5 of each cycle until the leukocyte original article Annals of Oncology count returned to normal. In both series, patients with limited disease (stages I-II) received four courses of VEBEP followed by irradiation of the involved fields (30 Gy), whereas patients with advanced disease (stages III-IV) received six courses of VEBEP followed by irradiation (32 Gy) of residual masses (i.e. nodes with a long axis ‡1.3 cm at CT) at the initial sites of bulky disease and/or of spleen plus the splenic hilar region in cases of pretreatment massive spleen involvement (more than five nodular lesions, as determined by the imaging techniques). After therapy completion, response to treatment was assessed by means of physical examination, laboratory tests, and imaging procedures [18, 25] . Patients classified as complete responders were followed-up by clinical and laboratory examinations, and contrast-enhanced CT scans. FDG-PET and biopsy procedures were carried out when clinically indicated.
statistical analysis
We tested the hypothesis that treatment strategy planned on the basis of the fused FDG-PET/CT staging approach resulted in a higher rate of EFS than side-by-side PET + CT staging, owing to a more accurate assessment of spleen and liver. A power analysis was carried out considering that in the pathological staging era, infiltration in spleen or liver is seen, at histological examination, in 30% and 10% of HL patients, respectively [6] [7] [8] [9] , whereas with separately carried out CT-and PET-based staging, infiltration in the spleen or liver is seen in <20% and 5% of patients, respectively [11] [12] [13] , and hence, a certain number of patients are understaged and undertreated. Our hypothesis was that in cohorts of a minimum of 98 patients each, we could obtain a statistically significant result if an absolute difference of 15% and 5% in detecting nodular infiltration in the spleen and liver, respectively, between side-by-side PET + CT staging and fused FDG-PET/CT staging is reached, with an 80% statistical power and 5% significance level (a error = 0.05, b error = 0.20). Because we assumed that 30% of patients would not be included in the efficacy analysis, we set an enrollment goal of at least 130 patients in each group.
Relapse, secondary malignancies, and death from any cause were considered events. EFS was calculated from the onset of chemotherapy up to the date of an event or the last follow-up visit; EFS was estimated by the Kaplan-Meier method and was compared between the cohorts by the log-rank test. For the statistical evaluations, the v 2 test was also carried out.
P values <0.05 were deemed statistically significant.
results
Thirty patients of the fused PET/CT group and 32 patients of the historical cohort were excluded from evaluation ( Figure 2 ). The main clinical features of the remaining 103 patients of the fused PET/CT group and the 100 patients of the historical cohort are reported in Table 1 . These 203 patients constituted the population analyzed. The two series were comparable with respect to the major variables known to affect clinical outcome. However, the Ann Arbor stage differed significantly between the two groups: 58 patients with limited disease and 45 with extensive disease in the fused PET/CT group versus 70 patients with limited disease and 30 with extensive disease in the historical cohort (P = 0.04). This difference was due to the different rate of spleen and liver involvement as a consequence of the different imaging modalities used. A total of 31 patients (30%) and 10 patients (10%) in the fused PET/CT group was found to have one or more distinct lymphoma nodules in spleen and liver, respectively, compared with only 14 patients (14%) and 3 patients (3%), respectively, in the historical cohort (Ps = 0.005 and 0.05, respectively). No patient had unequivocal palpable splenomegaly or hepatomegaly. A similar rate of subdiaphragmatic lymph node, lung, or bone involvement was observed in the two series (Table 2 ). In the fused PET/CT group, we carried out FDG-PET versus diagnostic CT scans (separately evaluated) analysis and compared the findings. There was complete agreement between the two procedures regarding the identification of splenic or hepatic focal lesions in 15 patients. On the contrary, the designation of splenic or hepatic focal lesions was discordant in 26 patients. In particular, FDG-PET identified at least one focal lesion in the spleen or liver in 9 of the 26 patients, whereas diagnostic CT identified at least one focal lesion in the spleen or liver in 17 of the 26 patients. The remaining 62 patients had normal spleen or liver status with each method.
fused PET/CT results
Fused PET/CT identified splenic lymphoma nodules in 31 patients: a single nodule was found in 8 patients (Figure 3) , and two or more nodules in 23 patients (two to four nodules in 5 patients; five or more nodules in 18 patients). The median long axis of splenic lymphoma nodules was 0.8 cm (range 0.5-3 cm). Fused PET/CT detected hepatic lymphoma nodules in 10 patients: a single nodule was found in 3 patients, and two or more nodules in 7 patients (Figure 3) . The median long axis of hepatic lymphoma nodules was <1 cm (median 0.8 cm, range 0.6-3 cm). The power of fused PET/CT in depicting minute lymphoma nodules is illustrated by the distribution of nodules according to their size in the two series. A similar number of patients with nodules >1 cm was observed in the two series. In contrast, fused PET/CT identified more patients with nodules £1 cm than side-by-side PET + CT (26 patients versus 3 patients; Figure 4 ). In the fused PET/CT group, 15 of 103 patients (14%) were upstaged to an extended disease, the spleen or the liver being the sole focus of intra-abdominal disease [i.e. stage III s with supradiaphragmatic lymph nodes and spleen involvement (n = 12); stage IV with supradiaphragmatic lymph nodes and liver involvement (n = 3)].
chemotherapy and radiotherapy received
As per protocol, all patients received 100% of the treatment scheduled on the basis of complete staging. After completion of chemotherapy (administered in each patient according to the Unless otherwise indicated, data are the number of patients. In both series, some patients had simultaneously several extranodal sites involved. original article Annals of Oncology stage, without dosage delays or reductions with respect to the standard treatment schedule shown in Figure 1 ), patients underwent the planned radiation therapy (Table 3) . In agreement with a high rate of subdiaphragmatic involvement found by fused PET/CT, compared with the historical cohort, significantly more patients of the fused PET/CT group received a schedule designed for an extensive disease, i.e. six courses of VEBEP (30% versus 44%, respectively; P = 0.04), and spleen area irradiation (7% versus 17%, respectively; P = 0.02). After treatment completion, all the 203 patients were classified as complete responders (CT negative and PET negative) and were observed thereafter.
EFS of analyzed patients
Overall, patients were observed for a median of 27 months (range 11-36 months). The median observation time was 26 months (range 13-32 months) in the fused PET/CT group and 29 months (range 11-36 months) in the historical cohort. The EFS of the entire population was 88%. During follow-up, the 24 events observed were not evenly distributed in the two series. Five of the 103 patients in the fused PET/CT group had lymph nodes positive for malignancy at histology (HL in 4 patients, metastasis of gastric cancer in a previously irradiated area in 1 patient) and achieved a 95% EFS. In contrast, 19 of the 100 patients in the historical cohort showed either lymph nodes positive for malignancy at histology (HL in 18 patients) or acute promyelocytic leukemia (1 patient), with an 81% EFS (P = 0.002). We carried out a subset analysis for EFS to identify subgroups of patients that would benefit more from treatment scheduled on the basis of fused PET/CT staging. Patients with limited-stage disease had a 97% EFS in the fused PET/CT group versus 83% in the historical cohort (P = 0.02). Patients with advanced-stage disease had a 93% EFS in the fused PET/CT group versus 77% in the historical cohort (P = 0.05; Figure 5 ).
patterns of HL relapse
Overall, 22 patients (11%) had HL recurrence. Four patients relapsed in the fused PET/CT group and 18 patients in the historical cohort (P = 0.001). CT and FDG-PET mapping showed that relapses were localized in nodal areas of supradiaphragmatic regions (n = 10), in nodal areas of supradiaphragmatic regions associated with lung involvement (n = 2), or in abdominal regions (n = 10). All abdominal relapses occurred in the historical cohort and were confined to liver, spleen, and para-aortic lymph nodes (n = 4) or to spleen plus para-aortic lymph nodes (n = 6); none were seen in previously irradiated sites (Table 4) . At the study end point, the 22 patients who relapsed are alive and in complete remission after salvage mobilizing chemotherapy followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. The two patients who suffered from secondary malignancies died.
outcome of patients not included. Sixty-two patients were excluded from the study because they did not meet the inclusion criteria (Figure 2 ). In particular, 18 patients who did not complete the staging procedure because of contraindications to contrast-agent injection did not receive the study treatment strategy. Twenty patients who had preexisting comorbidities (cardiopathy, n = 8; pneumopathy, n = 9; diabetes mellitus, n = 3) had 30%-50% dosage reduction of the VEBEP schedule since the first course. Seven patients (after the first two courses of the standard VEBEP schedule) required delays and reductions of chemotherapy dosage due to acute toxicity (infections), and 17 patients were lost to follow-up. Among the 27 patients who did not receive the VEBEP schedule at standard dosage, 16 patients did not achieve complete remission at the end of treatment.
discussion
The results reported herein indicate that it is possible to obtain an accurate assessment of spleen and liver in HL patients by using fused FDG-PET/contrast-enhanced CT scans and that pretreatment staging that includes this imaging modality improves EFS. In this study, 103 prospectively evaluated HL patients underwent a combined treatment strategy consisting of a number of VEBEP chemotherapy courses with or without irradiation planned on the basis of pretreatment risk factors, namely limited versus advanced stages, bulky disease, and/or massive spleen involvement. We excluded from the evaluation patients with contraindications to diagnostic contrast agents, and patients in whom comorbidities and/or acute toxicity did not allow them to receive the complete therapeutic program, thus avoiding those patients who were not appropriately treated for risk factors. We compared this group of 103 patients with a historical cohort of patients treated with the same therapeutic program in our institution before the introduction of fused PET/CT staging. The two series were well balanced for clinical features and also for stages evaluated according to conventional clinical and CT criteria [22, 23, 25] (data not shown). However, there were more patients with advanced disease in the study group than in the historical cohort, and this was because fused PET/ CT detected more spleen and liver involvements than side-byside PET + CT (the imaging modality used in the historical cohort). At 32 months, the rates of EFS of patients in the fused Data are the numbers of patients. VEBEP is the induction chemotherapy regimen used in the study (see text). T-field: irradiation of low neck and mediastinum; mantle: irradiation of the lymph node sites above the diaphragm; inverted Y: irradiation of para-aortic and pelvic lymph nodes; residual mass: irradiation of residual nodes at the initial bulky sites; spleen area: irradiation of spleen plus splenic hilar region in cases of pretreatment massive spleen involvement. original article
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PET/CT group, both those with limited disease (97%) and those with advanced disease (93%), were clearly better than in patients of the historical cohort. A possible explanation of this finding is that some patients of the historical cohort (especially those with limited disease) were understaged because the imaging procedures failed to identify spleen and/or liver occult involvement, and, according to treatment policy, they were treated with a regimen for more limited disease. During followup, the rate of relapses involving the splenic and liver region was higher in the historical cohort than in the fused PET/CT group (Table 4 ). This finding is important. Indeed, it confirms that four cycles of anthracycline-containing chemotherapy and nonsplenic irradiation may not be sufficient to eradicate occult subdiaphragmatic involvement, and implicates the spleen as a reservoir for hematogenic spread of disease after therapy completion [2, 3] . By contrast, fused PET/CT proved to be able to identify the subset of patients (18%) with involved sites at greatest risk for drug failure, namely spleen and liver, who benefited from more intensive treatment, i.e. six courses of anthracycline-containing chemotherapy followed by the prompt application of consolidation radiation of spleen and its adjacent lymph node areas. Indeed, the risk of relapse was fourfold lower in patients of the fused PET/CT group than in patients of the historical cohort.
We found a high rate of small lymphoma nodules in spleen and liver with the fused FDG-PET/contrast-enhanced CT procedure, using intrinsically aligned functional and morphological datasets acquired in a single imaging session. We attributed this advantage to the simultaneous combined use of i.v. CT contrast with FDG-PET acquisitions. Co-registering 
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areas of organs, which physiologically have background activity of glucose metabolism, with X-ray powered by injector for rapid bolus administration of i.v. contrast material (in hepatic arterial and portal venous phases) results in a synergic effect that is fundamental in depicting a small volume of FDG-avid neoplastic cells [26, 27] . Conversely, FDG-PET and contrastenhanced CT carried out separately, typically acquired on separate imaging systems, might not effectively depict small neoplastic nodules because of differences between the two procedures in the coaxial imaging range, the respiration state, and the location of movable organs, thereby jeopardizing the accuracy of imaging assessment [26] [27] [28] . Moreover, although the control was historical and the comparison of outcomes provides only circumstantial evidence of an improvement of fused FDG-PET/CT over the procedures carried out separately, these limitations are partly overcome by our observation that, when evaluated separately in the fused PET/CT group, the results of both procedures were similar to the findings obtained in the historical control.
There are a number of limitations in our study. First, larger and longer prospective studies are needed to confirm the validity of tumor control and the adverse sequelae data of combined modality treatment in HL patients staged with fused PET/CT. However, the better EFS of the patients in the fused PET/CT group as compared with that of the patients in the historical cohort limits the feasibility of a randomized trial for obvious ethical reasons. Second, the absence of histological proof could be considered a possible source of bias (overestimation of fused PET/CT results). However, the percentage of spleen and liver infiltration found by the fused PET/CT is very similar to that reported in previous series of HL patients undergoing pathological staging, in whom spleen and liver involvement was diagnosed through splenectomy and wedge liver biopsy [1, 2, [6] [7] [8] [9] 13] . Third, contrast-enhanced harmonic compound ultrasonography is an easy-to-use and accurate procedure for spleen assessment [15, 29] . However, the superiority of fused PET/CT over ultrasonography in providing a complete imaging staging in a single diagnostic occasion is unquestionable. Fourth, we used a nonconventional chemotherapeutic regimen as induction treatment. Our anthracycline-containing regimen may not be as efficient as more widely used treatments (e.g. adriamycin, bleomycin, vinblastine, dacarbazine) [30] . However, it is noteworthy that EFS was 95% at 32 months in our fused PET/CT group, which included all HL stages, without a relevant increase in sideeffects (only three patients required toxicity-related treatment reduction during chemotherapy). Finally, the use of FDG-PET combined with contrast-enhanced low-dose CT may reduce the patient's exposure to radiation without affecting diagnostic accuracy [17] .
In conclusion, our study underlines the importance of accurate staging to optimize the treatment of patients with HL. We propose fused FDG-PET/contrast-enhanced CT, which is a single imaging modality, be used for staging because it provides an accurate assessment of the spleen and liver status. The fused procedure identifies a subset of patients who need more intensive chemotherapy and spleen area irradiation to reduce the risk of relapse [2] [3] [4] [5] .
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